Microglia, a key immune cell in the brain, appears to mediate the relationship between the gut microbiome and amyloid-beta deposits in male mouse models of Alzheimer's disease.
A drug currently being tested in cancer clinical trials appears to prevent dysfunction in an immune cell signaling pathway associated with Alzheimer's disease. Blocking the pathway could prevent Alzheimer's from developing and slow the progression of symptoms for those who already have the disease.
Physical activity appears to reduce microglial activation and improve cognition in the aging human brain, researchers report.
Researchers examine how neuroimmune interactions promote brain plasticity and shed new light on how neuroimmune activity may have implications for a range of disorders, including neurological changes experienced by COVID-19 survivors.
Deleting ABI3, a gene associated with Alzheimer's disease, significantly increased amyloid-beta accumulation in the brain and decreased the amount of microglia around amyloid-plaques, researchers report.
Study reveals microglia play an important role in the maintenance of blood delivery to the brain. The findings may prove important to the study and treatment of cognitive decline, dementia, and stroke.
In the early stages of neurodegenerative diseases, microglia consume glucose to a greater extent than previously believed. The findings may serve as a new biomarker for a range of neurodegenerative disorders.
Analyzing the gene activity of 66,000 cells from human brain tissue, researchers generated a comprehensive map of cell types associated with brain lesions in multiple sclerosis, and their gene expression patterns and interactions.